Deutsche Bank Aktiengesellschaft Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)
Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The firm set a “hold” rating and a $136.00 price target on the biotechnology company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of […]
![Deutsche Bank Aktiengesellschaft Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)](https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/sarepta-therapeutics-inc-logo-1200x675.png?v=20240430120159&w=240&h=240&zc=2)